Avenues for identifying drug candidates forASXL1/2-mutated myeloid malignancies include studying the biological effects ofASXL1 versusASXL2 loss in the presence of cooperating mutations such as AML1-ETO. The gene discussed is RUNX1T1; the disease is myeloid neoplasm.